News
BMS and Nektar end collaboration for bempegaldesleukin + Opdivo
Nektar Therapeutics and Bristol Myers Squibb announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
These studies and all other ongoing studies in the program will be discontinued.
Condition: Breast Cancer Triple Neg
Type: drug